FX.co ★ Viracta Therapeutics Appoints Faerm As CFO

Viracta Therapeutics, Inc. (NASDAQ: VIRX) announced the immediate appointment of Michael Faerm as Chief Financial Officer on Tuesday. Faerm boasts over 25 years of experience in the life sciences sector, encompassing roles in equity research and investment banking. Prior to this, he served as the Interim Chief Financial Officer at Harpoon Therapeutics, Inc. In pre-market trading on the Nasdaq, Viracta's shares have risen 1.45% to $0.77.